Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice

Authors: Bart JM Eskens, Coert J Zuurbier, Judith van Haare, Hans Vink, Jurgen WGE van Teeffelen

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

The anti-diabetic drug metformin has been demonstrated to exert a protective effect against vascular complications in diabetes independent of its glucose lowering action. Since the endothelial glycocalyx has been indicated to have important vasculoprotective properties and to be vulnerable to degradation by hyperglycemic conditions, we evaluated in the current study the effect of short-term metformin treatment on whole-body glycocalyx barrier properties in a mouse model of non-insulin dependent diabetes mellitus (db/db mouse).

Methods

Glycocalyx barrier properties were measured in an acute experiment in three groups of mice: 1) db/db mice without treatment serving as controls, 2) db/db mice which received metformin for two weeks in the drinking water serving as experimental group, and 3) C57Bl/6 mice serving as reference group. Animals were put under anesthesia (ketamine, medetomidine, and atropine) and carotid artery blood pressure was continuously monitored. To probe the glycocalyx a mixture of the tracers FITC-labeled 70 kDa dextrans (Dex70) or fluorescein-labeled red blood cells (RBCs) versus Texas Red-labeled 40 kDa dextrans (Dex40) was infused and blood samples subsequently collected for 30 min to determine the initial vascular distribution volume and clearance of these tracers. Urine was collected and dry-to-wet weight of heart and kidney were determined after the experiment. Group differences were tested using unpaired t-tests.

Results

Metformin treatment did not affect body weight, fasting blood glucose and arterial blood pressure. Compared to C57Bl/6 mice, db/db mice showed a diminished initial exclusion and increased vascular clearance of Dex70 versus Dex40 (P < 0.05), and both were improved by the metformin treatment (P < 0.05). While urine production was higher in the db/db mice compared to C57Bl/6 (P < 0.05), heart and kidney of the metformin treated animals showed comparable dry-to-wet weights compared to the C57Bl/6 mice.

Conclusions

Two weeks of metformin in the drinking water is associated with an improvement in glycocalyx barrier properties in db/db mice, as evidence by an enhanced exclusion and retention of 70 kDa dextrans in the vasculature. In addition, metformin improved hydration of heart and kidney. Previous reported cardiovascular benefits of metformin may well involve an improvement of the endothelial glycocalyx.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med. 2002, 137: 25-33. 10.7326/0003-4819-137-1-200207020-00009.CrossRefPubMed Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med. 2002, 137: 25-33. 10.7326/0003-4819-137-1-200207020-00009.CrossRefPubMed
3.
go back to reference Matthaei S, Reibold JP, Hamann A, Benecke H, Haring HU, Greten H, Klein HH: In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology. 1993, 133: 304-311. 10.1210/en.133.1.304.PubMed Matthaei S, Reibold JP, Hamann A, Benecke H, Haring HU, Greten H, Klein HH: In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology. 1993, 133: 304-311. 10.1210/en.133.1.304.PubMed
4.
go back to reference Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WGT, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004, 279: 43940-43951. 10.1074/jbc.M404421200.CrossRefPubMed Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WGT, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004, 279: 43940-43951. 10.1074/jbc.M404421200.CrossRefPubMed
5.
go back to reference UK prospective diabetes study (UKPDS) group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet. 1998, 352: 854-865.CrossRef UK prospective diabetes study (UKPDS) group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet. 1998, 352: 854-865.CrossRef
6.
go back to reference Bailey CJ: Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008, 22: 215-224. 10.1007/s10557-008-6092-0.CrossRefPubMed Bailey CJ: Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008, 22: 215-224. 10.1007/s10557-008-6092-0.CrossRefPubMed
7.
go back to reference Wiernsperger N: 50 years later: is metformin a vascular drug with antidiabetic properties?. Brit J Diab Vasc Dis. 2007, 7: 204-210. 10.1177/14746514070070050201.CrossRef Wiernsperger N: 50 years later: is metformin a vascular drug with antidiabetic properties?. Brit J Diab Vasc Dis. 2007, 7: 204-210. 10.1177/14746514070070050201.CrossRef
8.
go back to reference Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM: Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005, 258: 250-256. 10.1111/j.1365-2796.2005.01531.x.CrossRefPubMed Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM: Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005, 258: 250-256. 10.1111/j.1365-2796.2005.01531.x.CrossRefPubMed
9.
go back to reference Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001, 37: 1344-1350. 10.1016/S0735-1097(01)01129-9.CrossRefPubMed Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001, 37: 1344-1350. 10.1016/S0735-1097(01)01129-9.CrossRefPubMed
10.
go back to reference De Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD: Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005, 257: 100-109. 10.1111/j.1365-2796.2004.01420.x.CrossRefPubMed De Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD: Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005, 257: 100-109. 10.1111/j.1365-2796.2004.01420.x.CrossRefPubMed
11.
go back to reference Katakam PV, Ujhelyi MR, Hoenig M, Miller AW: Metformin improves vascular function in insulin-resistant rats. Hypertension. 2000, 35: 108-112. 10.1161/01.HYP.35.1.108.CrossRefPubMed Katakam PV, Ujhelyi MR, Hoenig M, Miller AW: Metformin improves vascular function in insulin-resistant rats. Hypertension. 2000, 35: 108-112. 10.1161/01.HYP.35.1.108.CrossRefPubMed
12.
go back to reference Wiernsperger NF: Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther. 2000, 2: 259-272. 10.1089/15209150050025230.CrossRefPubMed Wiernsperger NF: Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther. 2000, 2: 259-272. 10.1089/15209150050025230.CrossRefPubMed
13.
go back to reference Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES: The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005, 16: 507-511. 10.1097/01.mol.0000181325.08926.9c.CrossRefPubMed Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES: The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005, 16: 507-511. 10.1097/01.mol.0000181325.08926.9c.CrossRefPubMed
14.
go back to reference Van Teeffelen JW, Brands J, Stroes ES, Vink H: Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med. 2007, 17: 101-105. 10.1016/j.tcm.2007.02.002.CrossRefPubMed Van Teeffelen JW, Brands J, Stroes ES, Vink H: Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med. 2007, 17: 101-105. 10.1016/j.tcm.2007.02.002.CrossRefPubMed
15.
go back to reference Lipowsky HH: The endothelial glycocalyx as a barrier to leukocyte adhesion and its mediation by extracellular proteases. Ann Biomed Eng. 2012, 40: 840-848. 10.1007/s10439-011-0427-x.PubMedCentralCrossRefPubMed Lipowsky HH: The endothelial glycocalyx as a barrier to leukocyte adhesion and its mediation by extracellular proteases. Ann Biomed Eng. 2012, 40: 840-848. 10.1007/s10439-011-0427-x.PubMedCentralCrossRefPubMed
16.
go back to reference Mochizuki S, Vink H, Hiramatsu O, Kajita T, Shigeto F, Spaan JA, Kajiya F: Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol. 2003, 285: H722-726.CrossRefPubMed Mochizuki S, Vink H, Hiramatsu O, Kajita T, Shigeto F, Spaan JA, Kajiya F: Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol. 2003, 285: H722-726.CrossRefPubMed
17.
go back to reference Constantinescu AA, Vink H, Spaan JA: Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol. 2003, 23: 1541-1547. 10.1161/01.ATV.0000085630.24353.3D.CrossRefPubMed Constantinescu AA, Vink H, Spaan JA: Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol. 2003, 23: 1541-1547. 10.1161/01.ATV.0000085630.24353.3D.CrossRefPubMed
18.
go back to reference Mulivor AW, Lipowsky HH: Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol. 2002, 283: H1282-1291. Mulivor AW, Lipowsky HH: Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol. 2002, 283: H1282-1291.
19.
go back to reference van den Berg BM, Vink H, Spaan JA: The endothelial glycocalyx protects against myocardial edema. Circ Res. 2003, 92: 592-594. 10.1161/01.RES.0000065917.53950.75.CrossRefPubMed van den Berg BM, Vink H, Spaan JA: The endothelial glycocalyx protects against myocardial edema. Circ Res. 2003, 92: 592-594. 10.1161/01.RES.0000065917.53950.75.CrossRefPubMed
20.
go back to reference Becker BF, Chappell D, Jacob M: Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010, 105: 687-701. 10.1007/s00395-010-0118-z.CrossRefPubMed Becker BF, Chappell D, Jacob M: Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010, 105: 687-701. 10.1007/s00395-010-0118-z.CrossRefPubMed
21.
go back to reference Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H: Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006, 55: 480-486. 10.2337/diabetes.55.02.06.db05-1103.CrossRefPubMed Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H: Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006, 55: 480-486. 10.2337/diabetes.55.02.06.db05-1103.CrossRefPubMed
22.
go back to reference Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB: Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006, 55: 1127-1132. 10.2337/diabetes.55.04.06.db05-1619.CrossRefPubMed Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB: Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006, 55: 1127-1132. 10.2337/diabetes.55.04.06.db05-1619.CrossRefPubMed
23.
go back to reference Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010, 53: 2646-2655. 10.1007/s00125-010-1910-x.PubMedCentralCrossRefPubMed Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010, 53: 2646-2655. 10.1007/s00125-010-1910-x.PubMedCentralCrossRefPubMed
24.
go back to reference Zuurbier CJ, Demirci C, Koeman A, Vink H, Ince C: Short-term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol. 2005, 99: 1471-1476. 10.1152/japplphysiol.00436.2005.CrossRefPubMed Zuurbier CJ, Demirci C, Koeman A, Vink H, Ince C: Short-term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol. 2005, 99: 1471-1476. 10.1152/japplphysiol.00436.2005.CrossRefPubMed
25.
go back to reference Vanteeffelen JW, Brands J, Janssen BJ, Vink H: Effect of acute hyaluronidase treatment of the glycocalyx on tracer-based whole body vascular volume estimates in mice. J Appl Physiol. 2013, 114: 1132-1140. 10.1152/japplphysiol.00842.2012.CrossRefPubMed Vanteeffelen JW, Brands J, Janssen BJ, Vink H: Effect of acute hyaluronidase treatment of the glycocalyx on tracer-based whole body vascular volume estimates in mice. J Appl Physiol. 2013, 114: 1132-1140. 10.1152/japplphysiol.00842.2012.CrossRefPubMed
26.
go back to reference VanTeeffelen JW, Brands J, Jansen C, Spaan JA, Vink H: Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension. 2007, 50: 261-267. 10.1161/HYPERTENSIONAHA.107.089250.CrossRefPubMed VanTeeffelen JW, Brands J, Jansen C, Spaan JA, Vink H: Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension. 2007, 50: 261-267. 10.1161/HYPERTENSIONAHA.107.089250.CrossRefPubMed
27.
go back to reference Meuwese MC, Broekhuizen LN, Kuikhoven M, Heeneman S, Lutgens E, Gijbels MJ, Nieuwdorp M, Peutz CJ, Stroes ES, Vink H, van den Berg BM: Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice. PloS one. 2010, 5: e14262-10.1371/journal.pone.0014262.PubMedCentralCrossRefPubMed Meuwese MC, Broekhuizen LN, Kuikhoven M, Heeneman S, Lutgens E, Gijbels MJ, Nieuwdorp M, Peutz CJ, Stroes ES, Vink H, van den Berg BM: Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice. PloS one. 2010, 5: e14262-10.1371/journal.pone.0014262.PubMedCentralCrossRefPubMed
28.
go back to reference Vink H, Duling BR: Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res. 1996, 79: 581-589. 10.1161/01.RES.79.3.581.CrossRefPubMed Vink H, Duling BR: Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res. 1996, 79: 581-589. 10.1161/01.RES.79.3.581.CrossRefPubMed
29.
go back to reference de Aguiar LG K, Laflor CM, Bahia L, Villela NR, Wiernsperger N, Bottino DA, Bouskela E: Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome. Diabet Med. 2007, 24: 272-279. 10.1111/j.1464-5491.2007.02082.x.CrossRef de Aguiar LG K, Laflor CM, Bahia L, Villela NR, Wiernsperger N, Bottino DA, Bouskela E: Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome. Diabet Med. 2007, 24: 272-279. 10.1111/j.1464-5491.2007.02082.x.CrossRef
30.
go back to reference Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D: Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol. 2012, 11: 61-10.1186/1475-2840-11-61.PubMedCentralCrossRefPubMed Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D: Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol. 2012, 11: 61-10.1186/1475-2840-11-61.PubMedCentralCrossRefPubMed
31.
go back to reference de Jager J, Kooy A, Schalkwijk C, van der Kolk J, Lehert P, Bets D, Wulffele MG, Donker AJ, Stehouwer CD: Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2013, doi: 10.1111/joim.12128. de Jager J, Kooy A, Schalkwijk C, van der Kolk J, Lehert P, Bets D, Wulffele MG, Donker AJ, Stehouwer CD: Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2013, doi: 10.1111/joim.12128.
32.
go back to reference Eriksson L, Erdogdu O, Nystrom T, Zhang Q, Sjoholm A: Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. Cardiovas Diab. 2012, 11: 27-10.1186/1475-2840-11-27.CrossRef Eriksson L, Erdogdu O, Nystrom T, Zhang Q, Sjoholm A: Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. Cardiovas Diab. 2012, 11: 27-10.1186/1475-2840-11-27.CrossRef
33.
go back to reference Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S: Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J. 2005, 52: 427-433. 10.1507/endocrj.52.427.CrossRefPubMed Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S: Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J. 2005, 52: 427-433. 10.1507/endocrj.52.427.CrossRefPubMed
34.
go back to reference Tang T, Reed MJ: Exercise adds to metformin and acarbose efficacy in db/db mice. Metabolism. 2001, 50: 1049-1053. 10.1053/meta.2001.25596.CrossRefPubMed Tang T, Reed MJ: Exercise adds to metformin and acarbose efficacy in db/db mice. Metabolism. 2001, 50: 1049-1053. 10.1053/meta.2001.25596.CrossRefPubMed
35.
go back to reference Verma S, Bhanot S, McNeill JH: Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther. 1994, 271: 1334-1337.PubMed Verma S, Bhanot S, McNeill JH: Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther. 1994, 271: 1334-1337.PubMed
36.
go back to reference Vink H, Duling BR: Capillary endothelial surface layer selectively reduces plasma solute distribution volume. Am J Physiol Heart Circ Physiol. 2000, 278: H285-289.PubMed Vink H, Duling BR: Capillary endothelial surface layer selectively reduces plasma solute distribution volume. Am J Physiol Heart Circ Physiol. 2000, 278: H285-289.PubMed
37.
go back to reference Henry CB, Duling BR: Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol. 1999, 277: H508-514.PubMed Henry CB, Duling BR: Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol. 1999, 277: H508-514.PubMed
38.
go back to reference VanTeeffelen JW, Constantinescu AA, Brands J, Spaan JA, Vink H: Bradykinin- and sodium nitroprusside-induced increases in capillary tube haematocrit in mouse cremaster muscle are associated with impaired glycocalyx barrier properties. J Physiol. 2008, 586: 3207-3218. 10.1113/jphysiol.2008.152975.PubMedCentralCrossRefPubMed VanTeeffelen JW, Constantinescu AA, Brands J, Spaan JA, Vink H: Bradykinin- and sodium nitroprusside-induced increases in capillary tube haematocrit in mouse cremaster muscle are associated with impaired glycocalyx barrier properties. J Physiol. 2008, 586: 3207-3218. 10.1113/jphysiol.2008.152975.PubMedCentralCrossRefPubMed
39.
go back to reference van Haaren PM, VanBavel E, Vink H, Spaan JA: Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol. 2003, 285: H2848-2856. van Haaren PM, VanBavel E, Vink H, Spaan JA: Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol. 2003, 285: H2848-2856.
40.
go back to reference Gao L, Lipowsky HH: Composition of the endothelial glycocalyx and its relation to its thickness and diffusion of small solutes. Microvasc Res. 2010, 80: 394-401. 10.1016/j.mvr.2010.06.005.PubMedCentralCrossRefPubMed Gao L, Lipowsky HH: Composition of the endothelial glycocalyx and its relation to its thickness and diffusion of small solutes. Microvasc Res. 2010, 80: 394-401. 10.1016/j.mvr.2010.06.005.PubMedCentralCrossRefPubMed
41.
go back to reference Cabrales P, Vazquez BY, Tsai AG, Intaglietta M: Microvascular and capillary perfusion following glycocalyx degradation. J Appl Physiol. 2007, 102: 2251-2259. 10.1152/japplphysiol.01155.2006.CrossRefPubMed Cabrales P, Vazquez BY, Tsai AG, Intaglietta M: Microvascular and capillary perfusion following glycocalyx degradation. J Appl Physiol. 2007, 102: 2251-2259. 10.1152/japplphysiol.01155.2006.CrossRefPubMed
43.
go back to reference Wiernsperger NF: Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab. 2003, 29: 579-585. 10.1016/S1262-3636(07)70072-1.CrossRefPubMed Wiernsperger NF: Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab. 2003, 29: 579-585. 10.1016/S1262-3636(07)70072-1.CrossRefPubMed
44.
go back to reference Vink H, Constantinescu AA, Spaan JA: Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion. Circulation. 2000, 101: 1500-1502. 10.1161/01.CIR.101.13.1500.CrossRefPubMed Vink H, Constantinescu AA, Spaan JA: Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion. Circulation. 2000, 101: 1500-1502. 10.1161/01.CIR.101.13.1500.CrossRefPubMed
45.
go back to reference Rubio-Gayosso I, Platts SH, Duling BR: Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol. 2006, 290: H2247-2256. Rubio-Gayosso I, Platts SH, Duling BR: Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol. 2006, 290: H2247-2256.
46.
go back to reference Valensi P, Behar A, Andre P, Wiernsperger N, Attali JR: The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema. Angiology. 1995, 46: 401-408. 10.1177/000331979504600506.CrossRefPubMed Valensi P, Behar A, Andre P, Wiernsperger N, Attali JR: The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema. Angiology. 1995, 46: 401-408. 10.1177/000331979504600506.CrossRefPubMed
47.
go back to reference Erdmann E: Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int J Cardiol. 2006, 107: 147-153. 10.1016/j.ijcard.2005.03.053.CrossRefPubMed Erdmann E: Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int J Cardiol. 2006, 107: 147-153. 10.1016/j.ijcard.2005.03.053.CrossRefPubMed
48.
go back to reference Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG: The endothelial glycocalyx: composition, functions, and visualization. Eur J Physiol. 2007, 454: 345-359. 10.1007/s00424-007-0212-8.CrossRef Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG: The endothelial glycocalyx: composition, functions, and visualization. Eur J Physiol. 2007, 454: 345-359. 10.1007/s00424-007-0212-8.CrossRef
49.
go back to reference Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M: Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Carv Res. 2010, 87: 300-310. 10.1093/cvr/cvq137.CrossRef Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M: Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Carv Res. 2010, 87: 300-310. 10.1093/cvr/cvq137.CrossRef
50.
go back to reference Bellin C, de Wiza DH, Wiernsperger NF, Rosen P: Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res. 2006, 38: 732-739. 10.1055/s-2006-955084.CrossRefPubMed Bellin C, de Wiza DH, Wiernsperger NF, Rosen P: Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res. 2006, 38: 732-739. 10.1055/s-2006-955084.CrossRefPubMed
51.
go back to reference Rosen P, Wiernsperger NF: Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diab/Metab Res Rev. 2006, 22: 323-330.CrossRef Rosen P, Wiernsperger NF: Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diab/Metab Res Rev. 2006, 22: 323-330.CrossRef
52.
go back to reference Ahmad S, Shahab U, Baig MH, Khan MS, Srivastava AK, Saeed M, Moinuddin : Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PloS one. 2013, 8: e72128-10.1371/journal.pone.0072128.PubMedCentralCrossRefPubMed Ahmad S, Shahab U, Baig MH, Khan MS, Srivastava AK, Saeed M, Moinuddin : Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PloS one. 2013, 8: e72128-10.1371/journal.pone.0072128.PubMedCentralCrossRefPubMed
53.
go back to reference Faure P, Wiernsperger N, Polge C, Favier A, Halimi S: Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci. 2008, 114: 251-256. 10.1042/CS20070276.CrossRefPubMed Faure P, Wiernsperger N, Polge C, Favier A, Halimi S: Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci. 2008, 114: 251-256. 10.1042/CS20070276.CrossRefPubMed
Metadata
Title
Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice
Authors
Bart JM Eskens
Coert J Zuurbier
Judith van Haare
Hans Vink
Jurgen WGE van Teeffelen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-175

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.